Akshat Jain: Asundexian for Recurrent Stroke Prevention
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn:
“How do we prevent Re-Stroke ?
Recurrent stroke remains a substantial unmet need despite secondary prevention. five-year recurrence risk can run approximately 10–12 percent in more recent cohorts.
The FDA’s November 9 approval of Sunharbo (asundexian) adds a new option for a defined population: adults with a recent non-cardioembolic ischemic stroke, NIHSS less than or equal to 15, or high-risk TIA. The approved regimen is 50 mg once daily in combination with antiplatelet therapy—not as a replacement for it.
Mechanism: targeting clot amplification
Asundexian is an oral, direct factor XIa inhibitor.
Concerns:
- Patient selection and bleeding still matter. The overall bleeding result should not be translated into ‘no increased bleeding risk.’ The FDA reports increased major bleeding in patients older than 75 and during the first 90 days, with gastrointestinal bleeding more common on asundexian.
- P-gp/strong CYP3A4 inducers, avoidance in moderate or severe hepatic impairment, and interruption around procedures and thrombolysis.
- NOT an atrial-fibrillation indication. OCEANIC-AF was stopped early for lack of efficacy; the secondary-prevention findings cannot be generalized across stroke mechanisms.
(My analysis of the study in the infographic)
The advance is meaningful. Its clinical value will depend on matching the treatment to the stroke mechanism and weighing absolute ischemic benefit against each patient’s bleeding risk.”
Stay updated with Hemostasis Today.
-
Nov 12, 2026, 10:28Ali Hammed: Should DOAC Use Exclude Patients From Thrombolysis After Ischemic Stroke?
-
Nov 12, 2026, 10:21Aseem Kumar Tiwari: The Molecular Dimension of HLA Matching
-
Nov 12, 2026, 10:18Sarah Connolly: Developing Advanced Haematology Services in Cancer Care
-
Nov 12, 2026, 10:13Carlos Esteban Gasko: Restrictive Transfusion in Critical Care
-
Nov 12, 2026, 10:07Samin Mohsenian: Advancing Care in Rare Bleeding Disorders
-
Nov 12, 2026, 10:03Influenza Vaccination in Patients With ITP – ITP Support Association
-
Nov 12, 2026, 09:57Romy Meier: From Research to New Scientific Perspectives on HIT and VITT
-
Nov 12, 2026, 09:50Denis Oduor: Did You Know What Happens to Your Body After You Donate Blood?
-
Nov 12, 2026, 09:49Care Beyond Borders for Women With Bleeding Disorders – EHC